Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function.

By C. Berridge, D. Devilbiss, Matthew E Andrzejewski, A. Arnsten, A. Kelley, B. Schmeichel, C. Hamilton, R. C. Spencer. Biological Psychiatry, 2006

620 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Cognitive Neuroscience, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/cef94cf70105975fa60fd472cdb2d86d0c6ff81c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. Trevor W. Robbins
2. A. Arnsten
3. Wolfram Schultz
4. Kent C. Berridge
5. J. Dalley
6. Andrea Bari
7. Barry J. Everitt

In Cognitive Neuroscience

1. Trevor W. Robbins
2. A. Arnsten
3. K. Tye
4. Wolfram Schultz
5. Michael J Frank
6. Kent C. Berridge
7. Joseph E LeDoux
8. J. Dalley

In Psychiatry and Mental health

1. Trevor W. Robbins
2. J. Dalley
3. Joseph E LeDoux

Citations in the corpus

• The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation (2009, background): “…and methylphenidate, as well as the atypical agent atomoxetine, enhance catecholamine transmission in PFC. Therapeutic doses of stimulants such as methylphenidate increase NE (and to a lesser extent, DA) in the PFC, while producing lesser effects in subcortical regions (Berridge et al. 2006).”